NCT05291897 (FIAT) is a clinical trial in Major Depressive Disorder Co-Occurrent With Anxiety, sponsored by Angelini Pharma Česká republika s.r.o..

Who is sponsoring NCT05291897?

NCT05291897 is sponsored by Angelini Pharma Česká republika s.r.o..

What condition does NCT05291897 study?

NCT05291897 studies Major Depressive Disorder Co-Occurrent With Anxiety, Adult Patients, Newly Diagnosed Depression.

Is NCT05291897 still recruiting?

NCT05291897 is currently terminated. Last updated 18 July 2023.

Last reviewed 2023-07-18 · How we verify

NCT05291897: FIAT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic

Terminated Last updated 18 July 2023

What this trial tests

trial in Major Depressive Disorder Co-Occurrent With Anxiety in 28 participants. Terminated before completion.

Timeline

15 October 2021

Primary endpoint
10 June 2023

30 June 2023

Quick facts

Lead sponsor	Angelini Pharma Česká republika s.r.o.
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	28
Start date	15 October 2021
Primary completion	10 June 2023
Estimated completion	30 June 2023
Sites	6 locations across Czechia

Conditions studied

Major Depressive Disorder Co-Occurrent With Anxiety — all drugs for Major Depressive Disorder Co-Occurrent With Anxiety →
Adult Patients — all drugs for Adult Patients →
Newly Diagnosed Depression — all drugs for Newly Diagnosed Depression →

Sponsor

Angelini Pharma Česká republika s.r.o.

Who can join

18 and older, any sex, with Major Depressive Disorder Co-Occurrent With Anxiety or Adult Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

According to the local guidelines (Recommendation for General Practitioners), the first choice Anti-Depressant (AD) in Major Depressive Disorder (MDD) in primary care should be selective serotonin reuptake inhibitors (SSRI), e.g. citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, in depression with anxiety and insomnia is preferable trazodone and in severer disorders mirtazapine. Despite all these molecules have a very good antidepressant effect, there are differences in side effect scale and tolerability. The aim of this Study is describing of real treatment practice and MDD management in primary care - aimed to evaluate effectiveness of the treatments in depression and related symptoms: insomnia, anxiety, anhedonia and sexual dysfunction. The primary objective of the Study is to describe the diagnostic process and treatment patterns in MDD- treatment of choice (pharmacologic with details of first choice antidepressant) in the office of GP's. The secondary objective is to evaluate efficiency of the treatments in depression and related symptoms: insomnia, anxiety, anhedonia and sexual dysfunction and to monitor the type of side effects and comedication during the 8-weeks treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05291897 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Angelini Pharma Česká republika s.r.o.
Last refreshed: 18 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05291897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing